Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00471)
Name
Niraparib
Synonyms    Click to Show/Hide the Synonyms of This API
Niraparib; 1038915-60-4; MK-4827; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; ZEJULA; MK4827; UNII-HMC2H89N35; Niraparib free base; MK 4827; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; 1038915-60-4 (free base); 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; 2-[4-(3S)-3-Piperidinylphenyl]-2H-indazole-7-carboxamide; Niraparib [USAN:INN]; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); GTPL8275; SCHEMBL1421875; DTXSID50146129; EX-A290; MK-4827 (PARP-1); 0919AA; ANW-62065; BDBM50316226; MFCD17779309; NSC754355; NSC800020; ZINC43206370; AKOS016004869; BCP9000940; CCG-267709; compound 56 [PMID 19873981]; CS-0780; DB11793; MK-4827/MK4827; NSC-754355; NSC-800020; SB16547; ZL-2306; NCGC00346435-01; NCGC00346435-04; AC-28447; AS-35248; HY-10619; JNJ-64091742; BCP0726000077; A11026; D10140; W-5696; Q25326660; 2-[4-[(3S)-3-Piperidyl]phenyl]indazole-7-carboxamide; 2H-Indazole-7-carboxamide, 2-[4-(3S)-3-piperidinylphenyl]
Clinical Status
Approved
Disease Indication Ovarian cancer ICD-11: 2C73 [1]
PubChem CID
24958200
Formula
C19H20N4O
Canonical SMILES
C1C[C@H](CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N
InChI
1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1
InChIKey
PCHKPVIQAHNQLW-CQSZACIVSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=24958200"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 320.4 Topological Polar Surface Area 72.9
XlogP 2.2 Complexity 449
Heavy Atom Count 24 Rotatable Bond Count 3
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 3
Full List of Drug Formulations (DFMs) Containing This API
          Niraparib 100 mg capsule Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Erythrosine sodium anhydrous; Lactose monohydrate; Fd&c blue no. 1; Fd&c yellow no. 5; Magnesium stearate; Titanium dioxide; Gelatin hydrolysate (porcine skin, mw 3000)
                   Dosage Form Oral Capsule
                   Company TESARO
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
FD&C blue no. 1 DIG Info Solute carrier SLCO2B1 (Ki = 13 uM) [2]
Hydrazine yellow DIG Info GABA(A) receptor alpha-1 (IC50 = 13 uM) [3]
Erythrosine sodium anhydrous DIG Info Multidrug resistance protein 3 (IC50 = 133000 nM) [4]
Gelatin DIG Info Mephenytoin 4-hydroxylase (EC50 = 20.5 uM) [5]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [6]
          Niraparib Tosylate 100mg capsule Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Magnesium Stearate; Lactose Monohydrate; Titanium Dioxide; Gelatin; Fd&C Blue 1; Fd&C Red 3; Fd&C Yellow 5; Gelatin; Shellac; Dehydrated Alcohol; Isopropyl Alcohol; Butyl Alcohol; Propylene Glycol; Purified Water; Strong Ammonia Solution; Potassium Hydroxide; Black Iron Oxide
                   Dosage Form Capsule
                   Company Glaxosmithkline
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
FD&C blue no. 1 DIG Info Solute carrier SLCO2B1 (Ki = 13 uM) [2]
FD&C yellow no. 5 free acid DIG Info Caspase-3 (IC50 = 100000 nM) [7]
Erythrosine sodium anhydrous DIG Info Multidrug resistance protein 3 (IC50 = 133000 nM) [4]
Isopropyl alcohol DIG Info Lymphoma P388/ADR cells (IC50 = 0.22 uM) [8]
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [9]
Gelatin DIG Info Mephenytoin 4-hydroxylase (EC50 = 20.5 uM) [5]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [6]
References
1 FDA label for approved niraparib from the official website of the U.S. Food and Drug Administration.
2 Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives. Proc Natl Acad Sci U S A. 2020 Jul 7;117(27):16009-16018.
3 The activities of drug inactive ingredients on biological targets. Science. 2020 Jul 24;369(6502):403-413.
4 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov; 136(1):216-41.
5 Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients. Mol Pharm. 2013 Jul 1;10(7):2739-48.
6 Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12.
7 PubChem BioAssay data set.
8 Synthesis and evaluation of dihydropyrroloquinolines that selectively antagonize P-glycoprotein. J Med Chem. 2004 Mar 11; 47(6):1413-22.
9 Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm. 2008 Sep;70(1):279-88.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.